
Genovis Q1 2023 - Strongest report to date

Redeye slightly ups its forecasts and valuation on the back of a strong Q1 2023 report, which marked the strongest performance to date in terms of both sales and profitability.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Genovis Q1 2023 - Strongest report to date